Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30352289 | 0.82 | KDM4E (0.62) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL1070561 | 0.82 | KDM4E (0.62) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL12606901 | 0.80 | NAPRT (0.55) | RAB9ANPC1LMNAKDM4EHTT | |
| SCHEMBL12828408 | 0.79 | RAB9A (0.67) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL49506 | 0.78 | RAB9A (0.65) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL12447388 | 0.78 | LMNA (0.57) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL29602550 | 0.78 | RAB9A (0.65) | RAB9ANPC1PKMLMNAHIF1A | |
| Hydrochloric Acid SCHEMBL5095381 | 0.76 | RAB9A (0.62) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL966665 | 0.76 | NPC1 (0.59) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL349933 | 0.76 | NAMPT (0.80) | RAB9ANPC1PKMLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970122-B1 | SHIP1 MODULATORS | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-05-08 | — | — | EP | disclosed |
| EP-2970122-B1 | SHIP1 MODULATORS | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-05-08 | — | — | EP | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-10174046-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-01-08 | — | — | US | disclosed |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2018-12-20 | — | — | US | disclosed |
| CN-108892637-A | SHIP1 regulator and relative method | 阿奎诺克斯药物(加拿大)公司 | 2018-11-27 | — | — | CN | disclosed |
| CN-108752236-A | SHIP1 conditioning agents and relative method | 阿奎诺克斯药物(加拿大)公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-105164108-B | SHIP1 modulators and methods related thereto | 阿奎诺克斯药物(加拿大)公司 | 2018-07-17 | — | — | CN | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20160031899-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-02-04 | — | — | US | disclosed |
| US-20160031899-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-02-04 | — | — | US | disclosed |
| EP-2970122-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| EP-2943470-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014158654-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014158654-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272081-B2 | SHIP1 modulators and methods related thereto | PPP1R1B, PPM1A, PPM1D | RAB9A 724/4885NPC1 776/4885PKM 4600/4885 |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1A, PPM1D, PPP1R1B | RAB9A 637/4885NPC1 702/4885PKM 4575/4885 |
| US-10174046-B2 | SHIP1 modulators and methods related thereto | PPM1D, PPP1R7, PPM1A | RAB9A 1329/4885NPC1 1709/4885PKM 4337/4885 |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | RAB9A 724/4885NPC1 776/4885PKM 4600/4885 |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | RAB9A 724/4885NPC1 776/4885PKM 4600/4885 |
| US-20160031899-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPM1A, PPP1R7 | RAB9A 1215/4885NPC1 1707/4885PKM 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.